American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
https://ascopubs.org/doi/full/10.1200/JCO.20.02953
Clinical Updates
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
https://meetinglibrary.asco.org/record/186976/slide
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
https://pubmed.ncbi.nlm.nih.gov/31160171/
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
https://www.ncbi.nlm.nih.gov/pubmed/30487236 Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC,…
Reducing Cancer Costs Through Symptom Management and Triage Pathways.
Barkley R1, Soobader MJ2, Wang J2, Blau S3, Page RD4.https://www.ncbi.nlm.nih.gov/pubmed/30576262
Artificial intelligence (AI) to improve patient outcomes in community oncology practices.
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e18098
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Slamon DJ1, Neven P1, Chia S1, Fasching PA1, De Laurentiis M1, Im SA1, Petrakova K1, Val Bianchi G1, Esteva FJ1, Martín M1, Nusch A1, Sonke GS1, De la Cruz-Merino L1, Beck JT1, Pivot X1, Sondhi M1, Wang Y1, Chakravartty A1, Rodriguez-Lorenc K1, Taran T1, Jerusalem…
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Piha-Paul SA1, Taylor MH2, Spitz D3, Schwartzberg L4, Beck JT5, Bauer TM6, Meric-Bernstam F1, Purkayastha D7, Karpiak L7, Szpakowski S8, Braiteh F9 https://www.ncbi.nlm.nih.gov/pubmed/31741715